Skip to main content

Advertisement

Table 1 Baseline characteristics and outcome of patients according to their pneumococcus colonization status

From: Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients

  Total n = 500 Not colonized n = 461 Colonized n = 39 P OR (CI95%)
Sex (male) - n (%) 322 (64.4) 291 (63.1) 31 (79.5) <0.05 (0.20–0.98)
Age years, median (range) 54.4 (45–64) 54.5 (45–64) 53.8 (42–64) ns
Type of transplant- n (%)
• Kidney 353 (70.6) 324 (70.3) 29 (74.4) ns
• Liver 106 (21.2) 100 (21.7) 6 (15.4)
• Heart 39 (7.8) 35 (7.6) 4 (10.3)
• Liver-kidney 2 (0.4) 2 (0.4) 0 (0)
Time from transplant, median (range)
• 0–180 days 94 (18.8) 88 (19.1) 6 (15.4) ns
• >180–360 days 34 (6.8) 31 (6.7) 3 (7.7)
• >1–5 years 139 (27.8) 131 (28.4) 8 (20.5)
• > 5 years 233 (46.6) 211 (45.8) 22 (56.4)
Charlson Comorbidity Index
• 0 point 110 (22) 103 (22.3) 7 (17.9) ns
• 1 points 94 (18.8) 89 (19.3) 5 (12.8)
• 2 points 83 (16.6) 76 (16.5) 7 (17.9)
• ≥3 puntos 213 (42.6) 193 (41.9) 20 (51.3)
Cohabiting children- n (%) 172 (34.4) 149 (32.3) 23 (59) 0.001 (1.55–5.87)
• Children pneumococcal vaccination 18 (3.6) 17 (4.3) 1 (2.8) ns
Prior pneumococcal infection- n (%) 44 (8.8) 38 (8.2) 6 (15.4) ns
Prior pneumococcal vaccine- n (%) 121 (24.2) 115 (24.9) 6 (15.4) ns
Baseline immunosuppression- n (%)     ns
• Tacrolimus 409 (81.8) 375 (81.3) 34 (87.2)  
• Mycophenolate 377 (75.4) 347 (75.3) 30 (76.9)
• Ciclosporine 58 (11.6) 55 (11.9) 3 (7.7)
• mTOR 79 (15.8) 75 (16.3) 4 (10.3)
• Azathyoprine 10 (2) 10 (2.2) 0 (0)
• Glucocorticoids 326 (65.2) 304 (65.9) 22 (56.4)
Thymoglobulin induction < 6 m- n (%) 28 (5.6) 26 (5.6) 2 (5.1) ns
Prior organ rejection 77 (15.4) 70 (15.2) 7 (17.9) ns
Outcomes: - n (%)
• Pneumococcal infection 3 2 (0.4) 1 (2.5) ns
• Death 9 9 (2) 0 (0)  
• Rejection 2 2 (0.4) 0 (0)  
• Graft loss 7 7 (1.6) 0 (0)  
  1. Abbreviations: OR odds ratio, CI Confidence Interval, mTOR mammalian Target of Rapamycin, ns not significant